Leerink Partners Initiates Coverage On Ligand Pharmaceuticals with Outperform Rating, Announces Price Target of $330
Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated LGND | 0.00 |
Leerink Partners analyst David Risinger initiates coverage on Ligand Pharmaceuticals (NASDAQ:
LGND) with a Outperform rating and announces Price Target of $330.